Navigation Links
Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
Date:12/3/2009

WALTHAM, Mass., Dec. 3 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (NYSE: IMA), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, has declared a dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock ( IMA-PB). The dividend will be paid in shares of Series B stock in an amount per share equal to the quotient of (a) $3.00 divided by (b) 97% of the average of the volume-weighted average price per share of the Series B stock on the New York Stock Exchange for each of the five consecutive trading days ending on the second trading day immediately prior to the record date of the dividend. Inverness will pay cash in lieu of any fractional shares resulting from the dividend. The dividend is payable on January 15, 2010 to holders of record of Series B stock at the close of business on January 4, 2010.

Such payment will cover the amount of all dividends accrued from October 1, 2009 through December 31, 2009.

For more information about Inverness Medical Innovations, please visit our website at http://www.invernessmedical.com.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. Inverness' global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

SOURCE Inverness Medical Innovations, Inc.


'/>"/>
SOURCE Inverness Medical Innovations, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 27, 2009 to Discuss Third Quarter 2009 Results
2. Inverness Medical Innovations - Concateno plc, Further Announcement Regarding UK Takeover Code Share Dealing Disclosure Requirements.
3. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
4. Inverness Medical Innovations Announces Third Quarter 2008 Results
5. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 29, 2008 to Discuss Third Quarter 2008 Results
6. Inverness Medical Innovations to Present at the UBS Global Life Sciences Conference on September 22, 2008
7. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
8. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
9. Inverness Medical Innovations to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008
10. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
11. Inverness Medical Innovations to Present at Canaccord Adams 28th Annual Growth Conference on August 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand ... 4.6 percent through 2020 to $7.2 billion.  This ... and beverages, cleaning products, biofuel production, animal feed, ... biotechnology, diagnostics, and biocatalysts). Food and beverages will ... driven by increasing consumption of products containing enzymes ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight Medical ... to the healthcare market. The company's primary focus is on new product introductions, ... strategies that are necessary to help companies efficiently bring their products to market. ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
Breaking Biology News(10 mins):